PPARGC1A and metabolic dysfunction-associated steatotic liver disease: Recent evidence suggests that hesperidin may potentially improve non-alcoholic fatty liver disease (NAFLD) by exerting hypoglycemic effects, promoting fatty acid β-oxidation through activating silent information regulator 1 (SIRT1)/ peroxisome proliferator-activated receptor gamma coactivator 1α (PGC1α), and, finally, modifying lipid profiles [14].